Lantheus Holdings, Inc. (FRA:0L8)

Market Cap	5.38B +9.1%
Revenue (ttm)	1.34B +0.6%
Net Income	242.00M +9.7%
EPS	3.61 +17.8%
Shares Out	n/a
PE Ratio	22.25
Forward PE	17.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	82.20
Previous Close	82.70
Day's Range	82.20 - 82.20
52-Week Range	41.91 - 88.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1956
• Employees: 1,193
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0L8

Financial Performance

In 2025, Lantheus Holdings's revenue was $1.54 billion, an increase of 0.50% compared to the previous year's $1.53 billion. Earnings were $233.56 million, a decrease of -25.25%.

Financial numbers in USD